• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Mirum Pharmaceuticals (MIRM)

Common Shares
Sell: $94.50|Buy: $100.01|Change: 0.50 (-0.52%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Address




Website

https://www.mirumpharma.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Mirum Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20262027-02-25T16:30:00
Mirum Pharmaceuticals Inc Fourth Quarter Earnings Results for 20262027-02-25T00:00:00
Mirum Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20262026-11-04T16:30:00
Mirum Pharmaceuticals Inc Third Quarter Earnings Results for 20262026-11-04T00:00:00
Mirum Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20262026-08-06T16:30:00
Mirum Pharmaceuticals Inc Second Quarter Earnings Results for 20262026-08-06T00:00:00
Mirum Pharmaceuticals Inc Annual General Meeting for 20262026-05-29T09:00:00
Mirum Pharmaceuticals Inc First Quarter Earnings Conference Call for 20262026-05-07T16:30:00
Mirum Pharmaceuticals Inc First Quarter Earnings Results for 20262026-05-07T00:00:00

Previous key dates

NameKey Date
2026 Leerink Partners Global Healthcare Conference2026-03-11T10:00:00
The Citizens Life Sciences Conference2026-03-10T10:10:00
TD Cowen’s 46th Annual Health Care Conference2026-03-02T13:10:00
Mirum Pharmaceuticals Inc Annual Report for 20252026-02-26T00:00:00
Mirum Pharmaceuticals Inc Fourth Quarter Earnings Conference Call for 20252026-02-25T16:30:00
Mirum Pharmaceuticals Inc Fourth Quarter Earnings Result for 20252026-02-25T00:00:00
44th Annual J.P. Morgan Healthcare Conference2026-01-14T11:15:00
Mirum Pharmaceuticals Business Update Call2025-12-08T08:30:00
Citi’s 2025 Global Healthcare Conference2025-12-03T00:00:00
8th Annual Evercore HealthCONx Conference2025-12-02T14:10:00
J.P. Morgan U.S. Opporunities Forum 20252025-11-12T00:00:00
2025 Stifel Healthcare Conference2025-11-11T08:40:00
Mirum Pharmaceuticals Inc Third Quarter Earnings Conference Call for 20252025-11-04T16:30:00
Mirum Pharmaceuticals Inc Third Quarter Earnings Result for 20252025-11-04T00:00:00
H.C. Wainwright 27th Annual Global Investment Conference2025-09-10T10:00:00
Baird 2025 Global Healthcare Conference2025-09-09T00:00:00
Morgan Stanley 23nd Annual Global Healthcare Conference2025-09-08T08:30:00
Cantor Global Healthcare Conference 20252025-09-04T15:20:00
Citi Biopharma Back-to-School Summit2025-09-03T00:00:00
Mirum Pharmaceuticals Inc Second Quarter Earnings Conference Call for 20252025-08-06T16:30:00
Mirum Pharmaceuticals Inc Second Quarter Earnings Result for 20252025-08-06T00:00:00
Mirum Pharmaceuticals Inc Annual General Meeting for 20252025-05-29T09:00:00
2025 RBC Capital Markets Global Healthcare Conference2025-05-21T09:00:00
3rd Annual H.C. Wainwright BioConnect Investor Conference2025-05-20T00:00:00
Mirum Pharmaceuticals Inc First Quarter Earnings Conference Call for 20252025-05-07T16:30:00
Mirum Pharmaceuticals Inc First Quarter Earnings Result for 20252025-05-07T00:00:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2026 AJ Bell. All rights reserved.